Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Barbara Ann Karmanos Cancer Institute
ClinicalTrials.gov Identifier:
NCT00030420
First received: February 14, 2002
Last updated: April 25, 2013
Last verified: April 2013

February 14, 2002
April 25, 2013
October 2001
May 2004   (final data collection date for primary outcome measure)
Efficacy of combining Celecoxib with Docetaxel [ Time Frame: Weeks 1 , 2 and 3 ] [ Designated as safety issue: No ]
Blood levels of VEGF & PGE2
Not Provided
Complete list of historical versions of study NCT00030420 on ClinicalTrials.gov Archive Site
  • Response rate of Celecoxib and Docetaxel [ Time Frame: Every 2 cycles (or every 42 days); After therapy is completed or if the patient is only on Celecoxib, will be assessed for progression every month by clinical exam and every 3 months by radiological evaluation. ] [ Designated as safety issue: No ]
    CT Chest/Abdomen
  • Toxicity of Celecoxib and Docetaxel [ Time Frame: Every week ] [ Designated as safety issue: Yes ]
    Routine bloodwork
  • Expression of cyclooxygenase-2 (COX-2) in tumors [ Time Frame: Pre-study ] [ Designated as safety issue: No ]
    Tissue sample from initial diagnosis, parrafin embedded tissue block
  • Changes in plasma levels of prostaglandin E2 (PGE2) & vascular endthelial growth factor (VEGF) [ Time Frame: Pre-study; Weeks 1 , 2 and 3 ] [ Designated as safety issue: No ]
    Collecting blood plasma
  • Vascular changes induced in the tumor by celecoxib [ Time Frame: Weeks 1, 3 & 6 ] [ Designated as safety issue: No ]
    Using DCE-MRI and PET scans to evaluate.
Not Provided
Not Provided
Not Provided
 
Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer
Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy

RATIONALE: Celecoxib may slow the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with celecoxib may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and docetaxel in treating patients who have advanced non-small cell lung cancer that has been previously treated with platinum-based chemotherapy.

OBJECTIVES:

  • Determine the efficacy and feasibility of celecoxib combined with docetaxel in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
  • Determine the response rate of patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral celecoxib twice daily (beginning on day -7 of the first course) and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses after CR. Patients who achieve stable disease (SD) or a partial response (PR) receive a minimum of 2 additional courses after SD or PR. At the discretion of the treating physician, patients then receive maintenance therapy comprising celecoxib only.

Patients who discontinue therapy for disease progression or unacceptable toxicity are followed for at least 6 months.

PROJECTED ACCRUAL: A total of 21-39 patients will be accrued for this study within 13-28 months.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lung Cancer
  • Drug: Celecoxib
    400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
    Other Names:
    • Celebrex
    • Celebra
    • Onsenal
  • Drug: Docetaxel
    On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
    Other Name: Taxotere
Experimental: Celecoxib & Docetaxel

Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.

Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days

Interventions:
  • Drug: Celecoxib
  • Drug: Docetaxel
Schneider BJ, Kalemkerian GP, Kraut MJ, Wozniak AJ, Worden FP, Smith DW, Chen W, Gadgeel SM. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. J Thorac Oncol. 2008 Dec;3(12):1454-9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
February 2008
May 2004   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of stage IIIA, IIIB, or IV non-small cell lung cancer

    • Disease progression during or after 1 or more platinum-based chemotherapy regimens
  • Measurable or evaluable disease
  • No symptomatic or untreated brain or leptomeningeal metastases

    • Previously treated patients must be neurologically stable for 4 weeks after completion of appropriate therapy

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • SWOG 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • Hemoglobin at least 8 g/dL

Hepatic:

  • Bilirubin no greater than upper limit of normal (ULN)
  • AST/ALT no greater than ULN (or no greater than 2.5 times ULN if alkaline phosphatase no greater than ULN)
  • Alkaline phosphatase no greater than ULN (or no greater than 5 times ULN if AST/ALT no greater than ULN)
  • No history of chronic hepatitis of any duration

Renal:

  • Creatinine no greater than ULN

Cardiovascular:

  • No uncontrolled congestive heart failure
  • No uncontrolled angina
  • No myocardial infarction and/or stroke within the past 6 months
  • No active thromboembolic event within the past 4 weeks

Gastrointestinal:

  • No gastrointestinal bleeding within the past 6 months
  • No history of peptic ulcer disease

Other:

  • No prior hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
  • No prior allergy to any non-steroidal anti-inflammatory drug
  • No other prior or concurrent malignancy within the past 3 years except adequately treated squamous cell or basal cell skin cancer or carcinoma in situ of the cervix
  • No grade 2 or greater peripheral neuropathy
  • No active infection
  • No other serious concurrent medical illness
  • No history of dementia, active psychiatric disorder, or other condition that would interfere with ability to take oral medication or preclude compliance with study
  • HIV negative
  • Must weigh at least 50 kg (110 pounds)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy
  • Prior paclitaxel allowed
  • No prior docetaxel

Endocrine therapy:

  • At least 3 days since prior steroids

Radiotherapy:

  • At least 4 weeks since prior radiotherapy
  • No prior radiotherapy to target lesion

Surgery:

  • At least 4 weeks since prior major surgery

Other:

  • Prior intermittent use of non-steroidal anti-inflammatory drugs (NSAIDs), including rofecoxib or celecoxib, allowed
  • At least 1 week since prior fluconazole
  • No recent prior NSAIDs, including rofecoxib or celecoxib, for a duration of more than 30 consecutive days
  • No concurrent fluconazole or lithium
  • No other concurrent NSAIDs except aspirin administered at a dose of no more than 325 mg/day for cardiovascular conditions
  • No other concurrent cyclo-oxygenase-2 inhibitors
  • No other concurrent investigational agents
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00030420
CDR0000069164, P30CA022453, WSU-C-2304, NCI-V01-1688
Yes
Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Study Chair: Shirish M. Gadgeel, MD Barbara Ann Karmanos Cancer Institute
Barbara Ann Karmanos Cancer Institute
April 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP